ArticleJGH open : an open access journal of gastroenterology and hepatology2026
Loss of Response to Anti-Tumor Necrosis Factor Alpha Therapy in Patients With Inflammatory Bowel Disease: A Real-World Comparison of Combination Therapy Versus Monotherapy.
Article in JGH open : an open access journal of gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The success of anti-TNFα agents has changed the landscape of treatment for inflammatory bowel diseases (IBD). One major limitation to this success is the secondary loss of response (sLOR) phenomenon. Combination therapy with immunomodulating agents has been shown to be effective in reducing the sLOR process. The primary aim of this study was to evaluate the rates of sLOR to anti-TNFα therapy in IBD patients on mono versus combination therapy, using real-world data. Methods: This was a retrospective study of 200 patients with IBD treated with anti-TNFα agents from 2000 to 2023. Data was collected on patient demographics, IBD phenotype, drug therapy, clinical and biochemical response to treatment. Results: Overall, there was no significant difference in median duration of response for infliximab (IFX) vs. adalimumab (ADA) (15 months, IQR 7-30 vs. 17 months, IQR 8-31; Conclusion: Combination therapy significantly reduced sLOR compared with monotherapy. There was no significant difference in sLOR between IFX and ADA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.